AstraZeneca's Lisa Anson elected president of ABPI

7 December 2016

Lisa Anson, president of AstraZeneca UK and Ireland, has been elected as the next president of trade group the Association of the British Pharmaceutical Industry (ABPI).

Ms Anson brings significant pharmaceutical industry experience to the role having held a variety of senior management roles at AstraZeneca (LSE: AZN) in the USA and the UK. Before joining AstraZeneca, she gained experience from a California based healthcare company and as a management consultant with KPMG. She holds a MBA with distinction from INSEAD in France and a First Class degree in Natural Sciences from Cambridge University.

She joined the ABPI board in January 2012 where she has been actively engaged in a number of capacities, leading on a number of key commercial projects such as implementing the Pharmaceutical Pricing Regulation Scheme – a unique deal with government which caps the total spend of branded medicines for the National Health Service (NHS) to ensure that UK patients get the medicines appropriate for them.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK